logo
OpenAI: ChatGPT Wants Legal Rights. You Need The Right To Be Forgotten.

OpenAI: ChatGPT Wants Legal Rights. You Need The Right To Be Forgotten.

Forbes8 hours ago
As systems like ChatGPT move toward achieving legal privilege, the boundaries between identity, ... More memory, and control are being redefined, often without consent.
When OpenAI CEO Sam Altman recently stated that conversations with ChatGPT should one day enjoy legal privilege, similar to those between a patient and a doctor or a client and a lawyer, he wasn't just referring to privacy. He was pointing toward a redefinition of the relationship between people and machines.
Legal privilege protects the confidentiality of certain relationships. What's said between a patient and physician, or a client and attorney, is shielded from subpoenas, court disclosures, and adversarial scrutiny. Extending that same protection to AI interactions means treating the machine not as a tool, but as a participant in a privileged exchange. This is more than a policy suggestion. It's a legal and philosophical shift with consequences no one has fully reckoned with.
It also comes at a time when the legal system is already being tested. In The New York Times' lawsuit against OpenAI, the paper has asked courts to compel the company to preserve all user prompts, including those the company says are deleted after 30 days. That request is under appeal. Meanwhile, Altman's suggestion that AI chats deserve legal shielding raises the question: if they're protected like therapy sessions, what does that make the system listening on the other side?
People are already treating AI like a confidant. According to Common Sense Media, three in four teens have used an AI chatbot, and over half say they trust the advice they receive at least somewhat. Many describe a growing reliance on these systems to process everything from school to relationships. Altman himself has called this emotional over-reliance 'really bad and dangerous.'
But it's not just teens. AI is being integrated into therapeutic apps, career coaching tools, HR systems, and even spiritual guidance platforms. In some healthcare environments, AI is being used to draft communications and interpret lab data before a doctor even sees it. These systems are present in decision-making loops, and their presence is being normalized.
This is how it begins. First, protect the conversation. Then, protect the system. What starts as a conversation about privacy quickly evolves into a framework centered on rights, autonomy, and standing.
We've seen this play out before. In U.S. law, corporations were gradually granted legal personhood, not because they were considered people, but because they acted as consistent legal entities that required protection and responsibility under the law. Over time, personhood became a useful legal fiction. Something similar may now be unfolding with AI—not because it is sentient, but because it interacts with humans in ways that mimic protected relationships. The law adapts to behavior, not just biology.
The Legal System Isn't Ready For What ChatGPT Is Proposing
There is no global consensus on how to regulate AI memory, consent, or interaction logs. The EU's AI Act introduces transparency mandates, but memory rights are still undefined. In the U.S., state-level data laws conflict, and no federal policy yet addresses what it means to interact with a memory‑enabled AI. (See my recent Forbes piece on why AI regulation is effectively dead—and what businesses need to do instead.)
The physical location of a server is not just a technical detail. It's a legal trigger. A conversation stored on a server in California is subject to U.S. law. If it's routed through Frankfurt, it becomes subject to GDPR. When AI systems retain memory, context, and inferred consent, the server location effectively defines sovereignty over the interaction. That has implications for litigation, subpoenas, discovery, and privacy.
'I almost wish they'd go ahead and grant these AI systems legal personhood, as if they were therapists or clergy,' says technology attorney John Kheit. 'Because if they are, then all this passive data collection starts to look a lot like an illegal wiretap, which would thereby give humans privacy rights/protections when interacting with AI. It would also, then, require AI providers to disclose 'other parties to the conversation', i.e., that the provider is a mining party reading the data, and if advertisers are getting at the private conversations.'
Infrastructure choices are now geopolitical. They determine how AI systems behave under pressure and what recourse a user has when something goes wrong.
And yet, underneath all of this is a deeper motive: monetization.
But they won't be the only ones asking questions.
Every conversation becomes a four-party exchange: the user, the model, the platform's internal optimization engine, and the advertiser paying for access. It's entirely plausible for a prompt about the Pittsburgh Steelers to return a response that subtly inserts 'Buy Coke' mid-paragraph. Not because it's relevant—but because it's profitable.
Recent research shows users are significantly worse at detecting unlabeled advertising when it's embedded inside AI-generated content. Worse, these ads are initially rated as more trustworthy until users discover they are, in fact, ads. At that point, they're also rated as more manipulative.
'In experiential marketing, trust is everything,' says Jeff Boedges, Founder of Soho Experiential. 'You can't fake a relationship, and you can't exploit it without consequence. If AI systems are going to remember us, recommend things to us, or even influence us, we'd better know exactly what they remember and why. Otherwise, it's not personalization. It's manipulation.' Now consider what happens when advertisers gain access to psychographic modeling: 'Which users are most emotionally vulnerable to this type of message?' becomes a viable, queryable prompt.
And AI systems don't need to hand over spreadsheets to be valuable. With retrieval-augmented generation (RAG) and reinforcement learning from human feedback (RLHF), the model can shape language in real time based on prior sentiment, clickstream data, and fine-tuned advertiser objectives. This isn't hypothetical—it's how modern adtech already works.
At that point, the chatbot isn't a chatbot. It's a simulation environment for influence. It is trained to build trust, then designed to monetize it. Your behavioral patterns become the product. Your emotional response becomes the target for optimization.
The business model is clear: black-boxed behavioral insight at scale, delivered through helpful design, hidden from oversight, and nearly impossible to detect.
We are entering a phase where machines will be granted protections without personhood, and influence without responsibility. If a user confesses to a crime during a legally privileged AI session, is the platform compelled to report it or remain silent? And who makes that decision?
These are not edge cases. They are coming quickly. And they are coming at scale.
Why ChatGPT Must Remain A Model—and Why Humans Must Regain Consent
As generative AI systems evolve into persistent, adaptive participants in daily life, it becomes more important than ever to reassert a boundary: models must remain models. They cannot assume the legal, ethical, or sovereign status of a person quietly. And the humans generating the data that train these systems must retain explicit rights over their contributions.
What we need is a standardized, enforceable system of data contracting, one that allows individuals to knowingly, transparently, and voluntarily contribute data for a limited, mutually agreed-upon window of use. This contract must be clear on scope, duration, value exchange, and termination. And it must treat data ownership as immutable, even during active use.
That means:
When a contract ends, or if a company violates its terms, the individual's data must, by law, be erased from the model, its training set, and any derivative products. 'Right to be forgotten' must mean what it says.
But to be credible, this system must work both ways:
This isn't just about ethics. It's about enforceable, mutual accountability.
The user experience must be seamless and scalable. The legal backend must be secure. And the result should be a new economic compact—where humans know when they're participating in AI development, and models are kept in their place.
ChatGPT Is Changing the Risk Surface. Here's How to Respond.
The shift toward AI systems as quasi-participants—not just tools—will reshape legal exposure, data governance, product liability, and customer trust. Whether you're building AI, integrating it into your workflows, or using it to interface with customers, here are five things you should be doing immediately:
ChatGPT May Get Privilege. You Should Get the Right to Be Forgotten.
This moment isn't just about what AI can do. It's about what your business is letting it do, what it remembers, and who gets access to that memory. Ignore that, and you're not just risking privacy violations, you're risking long-term brand trust and regulatory blowback.
At the very least, we need a legal framework that defines how AI memory is governed. Not as a priest, not as a doctor, and not as a partner, but perhaps as a witness. Something that stores information and can be examined when context demands it, with clear boundaries on access, deletion, and use.
The public conversation remains focused on privacy. But the fundamental shift is about control. And unless the legal and regulatory frameworks evolve rapidly, the terms of engagement will be set, not by policy or users, but by whoever owns the box.
Which is why, in the age of AI, the right to be forgotten may become the most valuable human right we have.
Not just because your data could be used against you—but because your identity itself can now be captured, modeled, and monetized in ways that persist beyond your control. Your patterns, preferences, emotional triggers, and psychological fingerprints don't disappear when the session ends. They live on inside a system that never forgets, never sleeps, and never stops optimizing.
Without the ability to revoke access to your data, you don't just lose privacy. You lose leverage. You lose the ability to opt out of prediction. You lose control over how you're remembered, represented, and replicated.
The right to be forgotten isn't about hiding. It's about sovereignty. And in a world where AI systems like ChatGPT will increasingly shape our choices, our identities, and our outcomes, the ability to walk away may be the last form of freedom that still belongs to you.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump pauses export controls to bolster China trade deal, FT says
Trump pauses export controls to bolster China trade deal, FT says

Yahoo

time3 minutes ago

  • Yahoo

Trump pauses export controls to bolster China trade deal, FT says

(Reuters) -The U.S. has paused curbs on tech exports to China to avoid disrupting trade talks with Beijing and support President Donald Trump's efforts to secure a meeting with President Xi Jinping this year, the Financial Times said on Monday. The industry and security bureau of the Commerce Department, which oversees export controls, has been told in recent months to avoid tough moves on China, the newspaper said, citing current and former officials. Reuters could not immediately verify the report. The White House and the department did not respond to Reuters' requests for comment outside business hours. Top U.S. and Chinese economic officials are set to resume talks in Stockholm on Monday to tackle longstanding economic disputes at the centre of a trade war between the world's top two economies. Tech giant Nvidia said this month it would resume sales of its H20 graphics processing units (GPU) to China, reversing an export curb the Trump administration imposed in April to keep advanced AI chips out of Chinese hands over national security concerns. The planned resumption was part of U.S. negotiations on rare earths and magnets, Commerce Secretary Howard Lutnick has said. The paper said 20 security experts and former officials, including former deputy US national security adviser Matt Pottinger, will write on Monday to Lutnick to voice concern, however. "This move represents a strategic misstep that endangers the United States' economic and military edge in artificial intelligence," they write in the letter, it added.

Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

Yahoo

time3 minutes ago

  • Yahoo

Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC

– Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – SOUTH SAN FRANCISCO, Calif., July 28, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. "Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition." Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. "Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis," said Matt Sause, CEO of Roche Diagnostics. "Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families." Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Pharmaceuticals In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Diagnostics Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm - 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm - 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm - 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm - 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am - 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am - 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley About trontinemab Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. About Roche in Alzheimer's Disease With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Genentech in Neuroscience Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit View source version on Contacts Media Contact: Meghan Hindman (650) 467-6800Advocacy Contact: Jenee Williams (650) 303-2958Investor Contacts: Loren Kalm (650) 225-3217Bruno Eschli +41616875284 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

McDonald's (MCD) Financial Health and Dividend Stability for Food Investors
McDonald's (MCD) Financial Health and Dividend Stability for Food Investors

Yahoo

time3 minutes ago

  • Yahoo

McDonald's (MCD) Financial Health and Dividend Stability for Food Investors

McDonald's Corporation (NYSE:MCD) is included among the 10 Best Food Stocks with Dividends. A cook in a busy kitchen assembling cheeseburgers for orders. McDonald's Corporation (NYSE:MCD) has evolved significantly since its peak in the mid-20th century, making ongoing efforts to stay current in a rapidly changing restaurant landscape. Despite some recent softness in sales, the company has managed to remain relevant. It's also favored by investors for its reliable dividend, having raised its payout every year since the mid-1970s— earning it Dividend King status. With a payout ratio near 60% of earnings, the company is well-positioned to sustain its dividend. McDonald's Corporation (NYSE:MCD) is prioritizing digital platforms, delivery services, and drive-thru operations to drive future sales growth. By enhancing its mobile app, expanding its loyalty program, and teaming up with third-party delivery providers, the company is working to lead in the delivery space while streamlining the ordering experience for customers. On July 23, McDonald's Corporation (NYSE:MCD) declared a quarterly dividend of $1.77 per share, which was in line with its previous dividend. The company has been growing its payouts for 48 consecutive years, which makes it one of the best food stocks with dividends. The stock has a dividend yield of 2.37%, as of July 27. While we acknowledge the potential of MCD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store